**Jefferson – Israel Health Tech R&D and Pilot Program**

**Call for Proposals**

The *Israel Innovation Authority* and *Thomas-Jefferson University - Jefferson Health*(Jefferson) invite interested Israeli companies to submit applications to collaborate in pilot and R&D healthcare-related technology activities Jefferson.

Jefferson and the Israel Innovation Authority are seeking to advance healthcare by helping Israeli companies get the evidence and assistance they need to fine-tune their development and to enter and be successful in the United States’ healthcare market.

Jefferson would serve as a real-world living laboratory for the Israeli companies to test and improve an existing process, service, or product; or to apply a new process to health care for the first time.

The goal of this collaboration is to accelerate the availability of medical innovations to the public, introduce Israeli healthcare technology to the U.S., and advance the development and deployment of discoveries for the benefit of patients everywhere.

The **Israel Innovation Authority** provides resources to aid technology advancement for Israeli companies.

***Jefferson*** is a large academic healthcare system that spans over Eastern Pennsylvania and Southern New Jersey. In addition to its traditional academic and clinical operations, Jefferson provides innovation-related expertise to companies to help advance clinical care and hospital operations.

The Israel Innovation Authority and Jefferson recently concluded a successful pilot program selecting four Israeli startup companies to receive grants to develop their innovative products at the Jefferson Health ecosystem. Jefferson is excited to share their experience and templates developed to assure future productive collaboration with the new selected applicants under this Call for Proposals.

**The following Jefferson strategic innovation assets and capabilities** serve as a “**sandbox” environment for *emerging innovative digital health solutions*** and can among other things **serve as a resource for Israeli companies**:

* Vicki and Jack Farber Institute for Neuroscience
* Sidney Kimmel Cancer Center
* National Academic Center for Telehealth – Thomas Jefferson University
* Center for Digital Health & Data Science – Thomas Jefferson University
* Institute for Smart and Healthy Cities
* Wills Eye Institute

**The health themes of interest to Jefferson include:**

* Technologies to support “Hospital at home” and “Healthcare with no address”
* Neuroscience:
* Brain computer interface, stem cell, exosomes
* Epilepsy, Headache, Parkinson& movement disorders, MS, Dementia
* Mobility solutions and Mobile Health
* Health information technology
* Clinical Decision Support and Team Management
* Telehealth
* Digital Prevention, Diagnosis, Treatment, Rehabilitation
* Biomaterials

**Application Process**

**Phase 1**

**Deadline for Expression of Interest (EOI) form submissions: 14/11/2022**

**Phase 2**

By 22/02/2023 the Israel Innovation Authority will invite Jefferson-selected Israeli companies to phase 2.

**Deadline for full submissions: 21/06/2023**

**Supported activities** may include: piloting, testing (of different kinds; including in real-world conditions), validation, trials, performance verification, device iteration, product and interface customization, pre-pilot activities, R&D activities needed for the pilot, optimizing the clinical use of a given technology/product, identifying the parameters of the product/technology and potential use cases, optimizing user interfaces, etc.

**What support do the Israel Innovation Authority and Jefferson offer?**

Successful Israeli applicant companies will receive funding from the Israel Innovation Authority. The Israel Innovation Authority can support R&D performing companies, registered and operating in Israel, with a grant of up to 50% of the approved R&D and Pilot Expenses Budget, according to its regulations and procedures. The Israeli companies must follow Israel Innovation Authority's rules and regulations, as described in the Hebrew website:

[**https://innovationisrael.org.il/international/rnd**](https://innovationisrael.org.il/international/rnd)

When a project eventually results in sales of a product, service, or process, the financial support must be repaid in royalties to the *Israel Innovation Authority* according to its regulations. In general, royalties are paid at rates beginning at 3% of sales, depending on various criteria. Royalties are payable until 100% of the amount of the grant has been repaid with interest as provided in the applicable regulations. If the project does not result in sales, no repayment is required.

Jefferson would provide assistance for the project and make it accessible through an applicable agreement with the selected Israeli companies. In the case of a pilot project, where no IP is shared, up to 10% of the project budget could be used to pay Jefferson for its services. In the case of a joint R&D project, where IP is shared, the costs of Jefferson could not be funded by the IIA.

Jefferson may provide in-kind services, expertise, and/or use of facilities. Examples for such in-kind support can include[[1]](#footnote-1):

* Usage of unique facilities for beta-sites operations;
* Access to real-field-conditions for the tested innovation;
* Usage of internal services, expertise, knowledge, or equipment;
* Access to unique data, datasets, engines, devices, skills;
* Possibility to recruit patients, experimenters, tools, etc. from the foreign entity;
* Experts' and consultants' time to guide, co-develop and, identify the parameters of the product/technology for testing or potential use cases;
* Regulatory and legal guidance to ensure full compliance;
* Assistance in co-commercializing the product; for example, through joint work with relevant local business partners (companies, investors, distributors, etc.) that are part of the foreign Jefferson's network.

An appropriate agreement between successful applicant companies and Jefferson will need to be signed as one of the first milestones during the project initiation.

**Process and Timeline**

|  |  |
| --- | --- |
| Program launch | September 2022 |
| Deadline for submission of Expression of Interest (EOI) | 14/11/2022 |
| Health centers select shortlisted companies, IIA invites shortlisted applicants to submit full application | 22/02/2023 |
| Deadline for full IIA online application | 21/06/2023 |
| IIA funding decision & project launch | September 2023 |

**Contacts**

|  |  |
| --- | --- |
| **Jefferson**  Zvi Grunwald, MD  Executive Director, The Jefferson Israel Center, Thomas Jefferson University  [Zvi.Grunwald@jefferson.edu](mailto:Zvi.Grunwald@jefferson.edu)  215-955-0866 | **Israel Innovation Authority**  International Collaborations Division  [InternationalCollaboration@innovationisrael.org.il](mailto:InternationalCollaboration@innovationisrael.org.il) |

1. Support may vary subject to the health center discretion. [↑](#footnote-ref-1)